{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T20:34:37Z","timestamp":1775680477596,"version":"3.50.1"},"reference-count":17,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,4,28]],"date-time":"2017-04-28T00:00:00Z","timestamp":1493337600000},"content-version":"vor","delay-in-days":117,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.vaccine.2016.11.076","type":"journal-article","created":{"date-parts":[[2016,12,4]],"date-time":"2016-12-04T23:15:21Z","timestamp":1480893321000},"page":"208-211","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Modelling the cost-effectiveness of catch-up \u2018MenB\u2019 (Bexsero) vaccination in England"],"prefix":"10.1016","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2388-9733","authenticated-orcid":false,"given":"Hannah","family":"Christensen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline L.","family":"Trotter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2016.11.076_b0005","unstructured":"Department of Health and Public Health England. JCVI position statement on use of Bexsero\u00ae meningococcal B vaccine in the UK. Available from: <https:\/\/www.gov.uk\/government\/publications\/meningococcal-b-vaccine-jcvi-position-statement>; 2014."},{"key":"10.1016\/j.vaccine.2016.11.076_b0010","unstructured":"Petitions UK Government and Parliament. Give the Meningitis B vaccine to ALL children, not just newborn babies. Available from: <https:\/\/petition.parliament.uk\/petitions\/108072>; 2016."},{"key":"10.1016\/j.vaccine.2016.11.076_b0015","doi-asserted-by":"crossref","first-page":"g5725","DOI":"10.1136\/bmj.g5725","article-title":"Re-evaluating cost effectiveness of universal meningitis vaccination (Bexsero) in England: modelling study","volume":"349","author":"Christensen","year":"2014","journal-title":"BMJ"},{"issue":"23","key":"10.1016\/j.vaccine.2016.11.076_b0020","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1016\/j.vaccine.2013.03.034","article-title":"Introducing vaccination against serogroup B meningococcal disease: an economic and mathematical modelling study of potential impact","volume":"31","author":"Christensen","year":"2013","journal-title":"Vaccine"},{"issue":"9960","key":"10.1016\/j.vaccine.2016.11.076_b0025","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1016\/S0140-6736(14)60842-4","article-title":"Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial","volume":"384","author":"Read","year":"2014","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.vaccine.2016.11.076_b0030","first-page":"220","article-title":"Meningococcal serogroup C conjugate vaccination in England and Wales: coverage and initial impact of the campaign","volume":"5","author":"Trotter","year":"2002","journal-title":"Communicable Dis Public Health"},{"issue":"43","key":"10.1016\/j.vaccine.2016.11.076_b0035","doi-asserted-by":"crossref","first-page":"4968","DOI":"10.1016\/j.vaccine.2013.08.006","article-title":"Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage","volume":"31","author":"Frosi","year":"2013","journal-title":"Vaccine"},{"issue":"9816","key":"10.1016\/j.vaccine.2016.11.076_b0040","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0140-6736(11)61713-3","article-title":"Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b\/3 randomised, observer-blind, placebo-controlled study","volume":"379","author":"Santolaya","year":"2012","journal-title":"Lancet"},{"issue":"9869","key":"10.1016\/j.vaccine.2016.11.076_b0045","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(12)61961-8","article-title":"Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials","volume":"381","author":"Vesikari","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2016.11.076_b0050","unstructured":"BMA NE, NHS England. Vaccination and Immunisation programmes 20126\/17. Guidance and audit requirements. Available from: <http:\/\/www.nhsemployers.org\/~\/media\/Employers\/Documents\/Primary%20care%20contracts\/V%20and%20I\/V%20and%20I%20Home%20Page\/VandI%20Guidance%20201617.pdf>; 2016."},{"key":"10.1016\/j.vaccine.2016.11.076_b0055","unstructured":"Joint Committee on Vaccination and Immunisation. Minute of the meeting on Tuesday 11 and Wednesday 12 February 2014. Available from: <https:\/\/app.box.com\/s\/iddfb4ppwkmtjusir2tc\/1\/2199012147\/18992168807\/1>."},{"key":"10.1016\/j.vaccine.2016.11.076_b0060","unstructured":"Joint Committee on Vaccination and Immunisation Code of Practice. Available from: <https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/224864\/JCVI_Code_of_Practice_revision_2013_-_final.pdf>; June 2013."},{"issue":"42","key":"10.1016\/j.vaccine.2016.11.076_b0065","doi-asserted-by":"crossref","first-page":"5436","DOI":"10.1016\/j.vaccine.2014.07.096","article-title":"Economic evaluation of meningococcal serogroup B childhood vaccination in Ontario, Canada","volume":"32","author":"Tu","year":"2014","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2016.11.076_b0070","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.4161\/hv.23888","article-title":"Cost-effectiveness of vaccination against meningococcal B among Dutch infants: crucial impact of changes in incidence","volume":"9","author":"Pouwels","year":"2013","journal-title":"Human Vaccines Immunother"},{"issue":"9","key":"10.1016\/j.vaccine.2016.11.076_b0075","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1017\/S095026881300294X","article-title":"Modelled evaluation of multi-component meningococcal vaccine (Bexsero\u00ae) for the prevention of invasive meningococcal disease in infants and adolescents in the UK","volume":"142","author":"Huels","year":"2014","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.vaccine.2016.11.076_b0080","unstructured":"Le Haut Conseil de la sant\u00e9 publique. Vaccination against serogroup B invasive meningococcal disease the role of Bexsero vaccination (in French). Available from: <http:\/\/www.hcsp.fr\/Explore.cgi\/Telecharger?NomFichier=hcspr20131025_vaccmeningocoqueBBexsero.pdf>; 2013."},{"issue":"12","key":"10.1016\/j.vaccine.2016.11.076_b0085","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S1473-3099(10)70251-6","article-title":"Meningococcal carriage by age: a systematic review and meta-analysis","volume":"10","author":"Christensen","year":"2010","journal-title":"Lancet Infect Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16311471?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16311471?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:22:31Z","timestamp":1759400551000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X16311471"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S0264410X16311471"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.11.076","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Modelling the cost-effectiveness of catch-up \u2018MenB\u2019 (Bexsero) vaccination in England","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.11.076","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}